Ikarian Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

$714 Million
Q1 2025

A detailed history of Ikarian Capital, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 75,000 shares of APLS stock, worth $1.31 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

75,000

Previous 3,594 1986.81%

Holding current value

$1.31 Million

Previous $114,000 1338.6%

% of portfolio

0.23%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$21.87 - $34.63 $1.56 Million - $2.47 Million	71,406 Added 1986.81%	75,000 $1.64 Million
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $94,090 - $127,299	3,594 New	3,594 $114,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $40,490 - $52,975	731 Added 2.13%	35,092 $2.06 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $1.28 Million - $2.23 Million	34,361 New	34,361 $2.06 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $2.59 Million - $3.15 Million	33,800 Added 33.8%	133,800 $12.2 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $4.66 Million - $6.7 Million	100,000 New	100,000 $6.6 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $10.7 Million - $18.1 Million	-305,645 Reduced 87.94%	41,900 $1.89 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $10.9 Million - $24.3 Million	347,545 New	347,545 $11.5 Million
Q4 2020 Feb 12, 2021	SELL	$30.79 - $57.2 $576,573 - $1.07 Million	-18,726 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $429,774 - $558,590	16,600 Added 780.81%	18,726 $565,000
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $1.24 Million - $1.92 Million	-50,000 Reduced 95.92%	2,126 $69,000
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $932,627 - $2.31 Million	52,073 Added 98250.94%	52,126 $1.4 Million
Q4 2019 Jan 31, 2020	BUY	$22.1 - $30.8 $1,171 - $1,632	53 New	53 $2,000

Others Institutions Holding APLS

# of Institutions

295

Shares Held

124M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $1.91B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History